Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano, Masayoshi Harigai, Taeko Ishii, Osamu Kawaguchi, Terence P. Rooney, Naotsugu Akashi & Tsutomu Takeuchi. (2018) Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Modern Rheumatology 28:4, pages 583-591.
Read now
Read now
Özgül Muştu Koryürek & Göknur Kalkan. (2016) A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 35:2, pages 145-152.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2015) Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology 25:4, pages 503-513.
Read now
Read now
Keisuke Izumi, Yuko Kaneko, Hidekata Yasuoka, Noriyuki Seta, Hideto Kameda, Masataka Kuwana & Tsutomu Takeuchi. (2015) Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52. Modern Rheumatology 25:1, pages 31-37.
Read now
Read now
Yoshiya Tanaka, Satoshi Kubo, Hisashi Yamanaka, Koichi Amano, Shintaro Hirata, Eiichi Tanaka, Hayato Nagasawa, Hidekata Yasuoka & Tsutomu Takeuchi. (2014) Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatology 24:5, pages 754-762.
Read now
Read now
Yoshiya Tanaka, Tsutomu Takeuchi, Koichi Amano, Kazuyoshi Saito, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Hideto Kameda, Yuko Kaneko, Takahiko Kurasawa, Hayato Nagasawa, Daisuke Hoshi, Eri Sato & Hisashi Yamanaka. (2014) Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Modern Rheumatology 24:3, pages 399-404.
Read now
Read now
Daisuke Hoshi, Ayako Nakajima, Kumi Shidara, Yohei Seto, Eiichi Tanaka, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2013) Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. Modern Rheumatology 23:6, pages 1205-1210.
Read now
Read now
Toshihisa Kojima, Yuichiro Yabe, Atsushi Kaneko, Yuji Hirano, Hisato Ishikawa, Masatoshi Hayashi, Hiroyuki Miyake, Hideki Takagi, Takefumi Kato, Kenya Terabe, Tsuyoshi Wanatabe, Hiroki Tsuchiya, Daihei Kida, Tomone Shioura, Koji Funahashi, Daizo Kato, Hiroyuki Matsubara, Nobunori Takahashi, Yosuke Hattori, Nobuyuki Asai & Naoki Ishiguro. (2013) Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Modern Rheumatology 23:5, pages 977-985.
Read now
Read now
Yuichiro Yabe, Toshihisa Kojima, Atsushi Kaneko, Nobuyuki Asai, Tomonori Kobayakawa & Naoki Ishiguro. (2013) A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. Modern Rheumatology 23:2, pages 245-253.
Read now
Read now
Toshihisa Kojima, Atsushi Kaneko, Yuji Hirano, Hisato Ishikawa, Hiroyuki Miyake, Hideki Takagi, Yuichiro Yabe, Takefumi Kato, Kenya Terabe, Naoki Fukaya, Hiroki Tsuchiya, Tomone Shioura, Koji Funahashi, Masatoshi Hayashi, Daizo Kato, Hiroyuki Matsubara & Naoki Ishiguro. (2012) Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Modern Rheumatology 22:3, pages 370-375.
Read now
Read now
Tsutomu Takeuchi, Yoshiya Tanaka, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Takahiko Kurasawa, Satoshi Kubo, Kazuyoshi Saito, Kumi Shidara, Noriko Kimura, Hayato Nagasawa, Hideto Kameda, Koichi Amano & Hisashi Yamanaka. (2012) Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology 22:3, pages 327-338.
Read now
Read now
Articles from other publishers (34)
Hongjie Qian, Jie Cheng, Yuzhou Gui, Wei Wang, Liyu Liang, Huijuan Zhu, Qingqing Wu, Meixian Ou, Qian Chen, Chen Yu & Jingying Jia. (2023) A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects. Clinical and Translational Science 16:9, pages 1704-1712.
Crossref
Crossref
Lieh-Bang Liou, Ping-Han Tsai, Yao-Fan Fang, Yen-Fu Chen, Chih-Chieh Chen & Jenn-Haung Lai. (2023) Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis. International Journal of Molecular Sciences 24:16, pages 12998.
Crossref
Crossref
Sweety Sharma, Somnath Basu, Ramesh K. Goyal, Parbhat K. Sahoo & Rajani Mathur. (2023) Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies. Journal of Pharmacology and Pharmacotherapeutics 13:4, pages 330-340.
Crossref
Crossref
Kosuke Ebina. (2022) Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis. Modern Rheumatology 32:2, pages 256-262.
Crossref
Crossref
Luca MASTORINO, Gianluca AVALLONE, Paolo DAPAVO, Martina MERLI, Andrea AGOSTINI, Damiano GRANDINETTI, Maria T. FIERRO, Pietro QUAGLINO & Simone RIBERO. (2022) Tocilizumab and its usage for skin diseases. Italian Journal of Dermatology and Venereology 157:1.
Crossref
Crossref
Javier Narváez, Teresa Oton, Judit Lluch, Maribel Mora-Limiñana, Joan Miquel Nolla & Estíbaliz Loza. (2022) La réponse aux antagonistes du récepteur de l’interleukine-6 dans la polyarthrite rhumatoïde est indépendante du nombre d’anti-TNF administrés auparavant : revue systématique et méta-analyse. Revue du Rhumatisme 89:1, pages 11-23.
Crossref
Crossref
Javier Narváez, Teresa Oton, Judit LLuch, Maribel Mora-Limiñana, Joan Miquel Nolla & Estíbaliz Loza. (2021) Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis. Joint Bone Spine 88:1, pages 105112.
Crossref
Crossref
Andriko Palmowski, Sabrina M. Nielsen, Thomas Buttgereit, Yannick Palmowski, Maarten Boers, Robin Christensen & Frank Buttgereit. (2020) Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta‐Regression Analyses. Arthritis Care & Research 72:10, pages 1490-1496.
Crossref
Crossref
Roberto Caporali, Walid K. H. Fakhouri, Claudia Nicolay, Harriet J. Longley, Serena Losi & Veronica Rogai. (2020) New Rheumatoid Arthritis Treatments for ‘Old’ Patients: Results of a Systematic Review. Advances in Therapy 37:9, pages 3676-3691.
Crossref
Crossref
Andriko Palmowski, Thomas Buttgereit, Yannick Palmowski, Sabrina M Nielsen, Maarten Boers, Robin Christensen & Frank Buttgereit. (2019) Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. Seminars in Arthritis and Rheumatism 48:6, pages 983-989.
Crossref
Crossref
Nessrine Akasbi, Amina Mounir, Francina Eddie Omboumahou Bakale, Samira El Fakir & Taoufik Harzy. (2019) Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice. Integrative Journal of Medical Sciences 6.
Crossref
Crossref
Aprajita Jagpal & Iris Navarro-Millán. (2018) Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatology 2:1.
Crossref
Crossref
Michael Nurmohamed, Ernest Choy, Sadiq Lula, Blerina Kola, Ryan DeMasi & Paola Accossato. (2018) The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. Drug Safety 41:5, pages 473-488.
Crossref
Crossref
Gablu Kilcher, Noemi Hummel, Eva M Didden, Matthias Egger & Stephan Reichenbach. (2018) Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology 57:2, pages 354-369.
Crossref
Crossref
Martin Soubrier, Jinglan Pei, Fr?d?rick Durand, Lars Gullestad & Ani John. (2016) Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy 4:1, pages 133-149.
Crossref
Crossref
Arman Ahmadzadeh, Alireza N. Farahmand & Latif Gachkar. (2017) Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis. International Journal of Rheumatic Diseases 20:2, pages 231-237.
Crossref
Crossref
Christina Charles-Schoeman, Miguel A. Gonzalez-Gay, Irina Kaplan, Mary Boy, Jamie Geier, Zhen Luo, Andrea Zuckerman & Richard Riese. (2016) Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Seminars in Arthritis and Rheumatism 46:1, pages 71-80.
Crossref
Crossref
Juan-Manuel Anaya, Carolina Duarte-Rey, Juan C. Sarmiento-Monroy, David Bardey, John Castiblanco & Adriana Rojas-Villarraga. (2016) Personalized medicine. Closing the gap between knowledge and clinical practice. Autoimmunity Reviews 15:8, pages 833-842.
Crossref
Crossref
Alla Ishchenko & Rik J. Lories. (2016) Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance. Drugs & Aging 33:6, pages 387-398.
Crossref
Crossref
Javier Narváez, Berta Magallares, César Díaz Torné, Maria Victoria Hernández, Delia Reina, Héctor Corominas, Raimon Sanmartí, Josep Maria LLobet, Arturo Rodriguez de la Serna & Joan Miquel Nolla. (2016) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Seminars in Arthritis and Rheumatism 45:4, pages 386-390.
Crossref
Crossref
Alejandro Balsa, Juan Víctor Tovar Beltrán, Rafael Cáliz Cáliz, Isabel Mateo Bernardo, Rosario García-Vicuña, Manuel Rodríguez-Gómez, Miguel Angel Belmonte Serrano, Carlos Marras, Eduardo Loza Cortina, Eva Pérez-Pampin & Vicente Vila. (2015) Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatology International 35:9, pages 1525-1534.
Crossref
Crossref
Christoph Minichsdorfer, Christine Wasinger, Evelyn Sieczkowski, Bihter Atil & Martin Hohenegger. (2015) Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells. Melanoma Research 25:4, pages 284-294.
Crossref
Crossref
Vivian P. Bykerk, Andrew J. K. Östör, José Alvaro-Gracia, Karel Pavelka, José Andrés Román Ivorra, Winfried Graninger, William Bensen, Michael T. Nurmohamed, Andreas Krause, Corrado Bernasconi, Maher Aassi & Jean Sibilia. (2015) Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clinical Rheumatology 34:3, pages 563-571.
Crossref
Crossref
Yves-Marie Pers, Roxane Schaub, Elodie Constant, Joseph Lambert, Marie Godfrin-Valnet, Clémentine Fortunet, Waafa Bourichi, Béatrice Pallot Prades, Daniel Wendling, Philippe Gaudin, Christian Jorgensen, Jean-Francis Maillefert & Hubert Marotte. (2015) Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine 82:1, pages 25-30.
Crossref
Crossref
Shinya Hirabara, Nobunori Takahashi, Naoki Fukaya, Hiroyuki Miyake, Yuichiro Yabe, Atsushi Kaneko, Takayasu Ito, Takeshi Oguchi, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Fumiaki Sugiura, Masatoshi Hayashi, Koji Funahashi, Masahiro Hanabayashi, Shuji Asai, Naoki Ishiguro & Toshihisa Kojima. (2014) Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clinical Rheumatology 33:9, pages 1247-1254.
Crossref
Crossref
Meghna Jani, Nik Hirani, Eric L. Matteson & William G. Dixon. (2013) The safety of biologic therapies in RA-associated interstitial lung disease. Nature Reviews Rheumatology 10:5, pages 284-294.
Crossref
Crossref
Yves-Marie Pers, Cl?mentine Fortunet, Elodie Constant, Joseph Lambert, Marie Godfrin-Valnet, Audrey De Jong, Gr?goire Mercier, B?atrice Pallot Prades, Daniel Wendling, Philippe Gaudin, Christian Jorgensen, Hubert Marotte & Jean-Francis Maillefert. (2014) Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 53:1, pages 76-84.
Crossref
Crossref
Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Hiroyuki Miyake, Takefumi Kato, Naoki Fukaya, Hisato Ishikawa, Masatoshi Hayashi, Seiji Tsuboi, Yasuhide Kanayama, Daizo Kato, Koji Funahashi, Hiroyuki Matsubara, Yosuke Hattori, Masahiro Hanabayashi, Shinya Hirabara, Kenya Terabe, Yutaka Yoshioka & Naoki Ishiguro. (2013) Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clinical Rheumatology 33:1, pages 39-47.
Crossref
Crossref
Jamie Robertson, Mike J. Peters, Iain B. McInnes & Naveed Sattar. (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology 9:9, pages 513-523.
Crossref
Crossref
R.J. Maneiro, Eva Salgado, Loreto Carmona & Juan J. Gomez-Reino. (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 43:1, pages 9-17.
Crossref
Crossref
Jutatip Guptarak, Sheshali Wanchoo, Julieann Durham-Lee, Yewen Wu, Dragoslava Zivadinovic, Adriana Paulucci-Holthauzen & Olivera Nesic. (2013) Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain 154:7, pages 1115-1128.
Crossref
Crossref
Atsushi OgataToru HiranoYoshihiro HishitaniToshio Tanaka. (2012) Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 5, pages CMAMD.S7371.
Crossref
Crossref
Toshio Tanaka, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata & Atsushi Kumanogoh. (2011) Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders. Drug Development Research 72:8, pages 717-732.
Crossref
Crossref
Ayako Nakajima. (2011) 2. IL-6 Inhibitor. Nihon Naika Gakkai Zasshi 100:10, pages 2972-2978.
Crossref
Crossref